This biotech is forecasted to grow at an annual rate of 35.60% over the next five years.
MannKind Corporation (MNKD)
From Nate’s Notes
My Top Pick for 2021 is once again MannKind. The company’s lead product, Afrezza (a form of ultra-fast acting mealtime insulin that is inhaled rather than injected), is finally starting to make some inroads with both type 1 and type 2 diabetics (and their doctors), and I expect this trend to start accelerating as we get further into the year.
In addition, the company has licensed its drug delivery platform (Technosphere) to United Therapeutics (UTHR), and United Therapeutics is moving forward aggressively with plans to commercialize a form of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and PAH associated with interstitial lung disease (ILD) using this platform (MannKind will receive royalties on sales if/when the drug is approved).
Along with this agreement, the company has also licensed the platform to a private company called Receptor Life Sciences that is using it to develop cannabinoid-based pharmaceutical products. After being the target of short sellers for the past few years, this group seems to finally be moving on, as the short interest, though still large, was essentially cut in half during 2020. MNKD is a strong buy under $5 and a buy under $10.
Nate Pile, Nate’s Notes, NotWallStreet.com, 707-433-7903, January 3, 2021